POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (10.22.2021, 5:45pm CEST, WHO):   U.S. 74,227    India 15,786    Brazil 15,609    United Kingdom 51,484    Russia 37,141    Turkey 28,465    France 5,498    Iran 11,788    Argentina 1,218    Columbia 1,224    Italy 3,791    Germany 19,572    Mexico 5,069    Poland 5,716    Philippines 4,806    Ukraine 23,785    Malaysia 6,210    Peru 1,034    Netherlands 5,223    Iraq 1,882    Thailand 9,810    Czechia 3,638    Canada 2,641    Chile 1,793    Romania 15,410    Serbia 7,327    Kazakhstan 1,893    Cuba 1,435    Vietnam 3,636    Hungary 2,548    Austria 3,818    Greece 3,376    Georgia 4,155    Belarus 2,097    Bulgaria 4,816    Azerbaijan 2,005    Slovakia 3,470    Croatia 3,258    Ireland 2,026    Venezuela 1,254    Lithuania 3,016    Denmark 1,247    South Korea 1,440    Moldova 1,787    Slovenia 1,845    Armenia 2,146    Latvia 3,133    Estonia 1,323    China 51    Singapore 3,439    New Zealand 134    Australia 2,643   

Novavax seeks WHO approval for COVID-19 vaccine

Christian Fernsby |
Novavax with its partner, Serum Institute of India (SII), announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.

Article continues below




The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).

NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall; and the PREVENT-19 trial in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response.

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 microgram antigen and 50 microgram Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels.


What to read next

Gavi signs agreement with Novavax to secure doses on behalf of COVAX
New vaccine to provide 2-year protection
World-first COVID-19 alternating dose vaccine study launches in UK